Piper Sandler has initiated coverage on 10X Genomics Inc (TXG) with a Neutral rating, marking the firm's first assessment of the company. This evaluation reflects Piper Sandler's research into the life sciences technology firm, which specializes in products designed to interrogate and understand biological systems.
Headquartered in Pleasanton, California, 10X Genomics operates within the Life Sciences Tools & Services industry. The company went public on September 12, 2019, and currently has a market capitalization of $2.1 billion. Its integrated solutions encompass instruments, consumables, and software for single-cell and spatial biology systems. Key products include the Chromium platform, which enables high-throughput analysis of individual biological components, and the Visium platform, designed for high-resolution spatial analysis of biological tissues.
As of the latest financial snapshot, 10X Genomics reported an earnings per share (EPS) of -0.62 for the trailing twelve months. Upcoming earnings are scheduled for August 5, 2026, with an estimated EPS of -0.24 and projected revenue of $151.1 million. Recent performance has shown fluctuations in EPS, with a notable surprise of 24.4% in Q3 2025, where the EPS was -0.22 compared to an estimate of -0.29.
Analyst ratings serve as professional opinions based on extensive research and financial modeling. While they can provide valuable insights, these assessments are subject to change as new information emerges. Investors are encouraged to consider a variety of factors, including company fundamentals and market trends, when making investment decisions.